Invion signs agreement with The Cho Group Limited to obtain exclusive commercialisation and distribution rights in Australia and New Zealand to NGPDT technologies for the treatment of all cancers Invion signs a global Research and Development Agreement to conduct clinical trials initially targeting prostate cancer The Cho Group will provide non-dilutive funding for all clinical…
Read more
